Background: It was initially suggested in the 1960s to use AFP as a tumor marker for hepatocellular carcinoma (HCC), AFP still plays a big part in HCC monitoring. Patients and methods: this study was conducted on 90 patients with liver diseases and 25 healthy control G1, patients were divided into 4 groups, (G2) 25 patients with HCV infection, (G3) 25 HCC+HCV infection, (G4) 25 patients with HBV infection, (G5) 15 patients with HCC + HBV. Results: there was a statistically significant difference between the five groups p-value >0.001^*, compared to the control group the three groups G2, G3, and G5 have the same statistically significant difference with the same p-value >0.001^*, while group 4 HBV patients have not statistically significant difference with p-value 0.254 compared to the control group, Serum AFP highly significant elevated in HCC patients associated with HCV or HBV infection patients.